Vimarsana
Biggest News Aggregation in the World

Page 32 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China's National Reimbursement Drug List - Vimarsana News

Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China's National Reimbursement Drug List

--Junshi Biosciences, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company’ s product toripalimab continues to be included in Category B in the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity...

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China's National Reimbursement Drug List - Vimarsana News

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China's National Reimbursement Drug List

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China’s National Reimbursement Drug List

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Delivers Second Phase of Normandy Complex - Vimarsana News

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Delivers Second Phase of Normandy Complex

Investegate announcements from Etalon Group PLC, Etalon Delivers Second Phase of Normandy Complex

Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma - Vimarsana News

Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

4th approved indication for toripalimabSHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences", HKEX: 1877; SSE: 688180) announced today that the

Kintor Pharma Receives IND Clearance by NMPA for KX-826's Pivotal Study to Treat Male Alopecia Patients - Vimarsana News

Kintor Pharma Receives IND Clearance by NMPA for KX-826's Pivotal Study to Treat Male Alopecia Patients

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com